New Findings Reported from University of California Los Angeles (UCLA) Describe Advances in Prostate Cancer (Tandem Isotope Therapy With 225ac-and 177lu-psma-617 In a Murine Model of Prostate Cancer).

A recent report from the University of California Los Angeles (UCLA) discusses the potential of radionuclide therapy for metastatic castration-resistant prostate cancer. The study compared the effectiveness of different treatments in a murine model of disseminated prostate cancer. The results showed that a combination of 225Ac and 177Lu-PSMA-617 resulted in decreased tumor growth compared to 177Lu alone, particularly in the microscopic disease setting. The research suggests that alpha-emitters like 225Ac may be preferable for treating prostate cancer. [Extracted from the article]

Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)